首页> 外文OA文献 >Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy
【2h】

Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy

机译:舒洛地特降低白蛋白尿并调节链脲佐菌素诱导的I型糖尿病肾病C57BL / 6小鼠的基质蛋白积累

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE:Sulodexide is a mixture of glycosaminoglycans that may reduce proteinuria in diabetic nephropathy (DN), but its mechanism of action and effect on renal histology is not known. We investigated the effect of sulodexide on disease manifestations in a murine model of type I DN.METHODS:Male C57BL/6 mice were rendered diabetic with streptozotocin. After the onset of proteinuria, mice were randomized to receive sulodexide (1 mg/kg/day) or saline for up to 12 weeks and renal function, histology and fibrosis were examined. The effect of sulodexide on fibrogenesis in murine mesangial cells (MMC) was also investigated.RESULTS:Mice with DN showed progressive albuminuria and renal deterioration over time, accompanied by mesangial expansion, PKC and ERK activation, increased renal expression of TGF-β1, fibronectin and collagen type I, III and IV, but decreased glomerular perlecan expression. Sulodexide treatment significantly reduced albuminuria, improved renal function, increased glomerular perlecan expression and reduced collagen type I and IV expression and ERK activation. Intra-glomerular PKC-α activation was not affected by sulodexide treatment whereas glomerular expression of fibronectin and collagen type III was increased. MMC stimulated with 30 mM D-glucose showed increased PKC and ERK mediated fibronectin and collagen type III synthesis. Sulodexide alone significantly increased fibronectin and collagen type III synthesis in a dose-dependent manner in MMC and this increase was further enhanced in the presence of 30 mM D-glucose. Sulodexide showed a dose-dependent inhibition of 30 mM D-glucose-induced PKC-βII and ERK phosphorylation, but had no effect on PKC-α or PKC-βI phosphorylation.CONCLUSIONS:Our data demonstrated that while sulodexide treatment reduced proteinuria and improved renal function, it had differential effects on signaling pathways and matrix protein synthesis in the kidney of C57BL/6 mice with DN.
机译:目的:舒洛地昔是糖胺聚糖的混合物,可降低糖尿病性肾病(DN)中的蛋白尿,但其作用机制和对肾脏组织学的作用尚不清楚。我们研究了舒洛地昔对Ⅰ型DN鼠模型疾病表现的影响。方法:用链脲佐菌素使雄性C57BL / 6小鼠患有糖尿病。蛋白尿发作后,将小鼠随机分组接受sulodexide(1 mg / kg / day)或生理盐水治疗长达12周,并检查肾功能,组织学和纤维化。结果:DN小鼠表现出逐步的白蛋白尿和肾功能随时间的推移而恶化,并伴有肾小球膜扩张,PKC和ERK活化,TGF-β1和纤连蛋白的肾脏表达增加。和I,III和IV型胶原蛋白,但肾小球Perlecan表达降低。 Sulodexide治疗可显着降低蛋白尿,改善肾功能,增加肾小球Perlecan表达并降低I型和IV型胶原表达以及ERK活化。舒洛地昔治疗不影响肾小球内PKC-α的活化,而纤连蛋白和III型胶原的肾小球表达增加。用30 mM D-葡萄糖刺激的MMC显示PKC和ERK介导的纤连蛋白和III型胶原合成增加。在MMC中,仅Sulodexide单独以剂量依赖的方式显着增加了纤连蛋白和III型胶原的合成,在30 mM D-葡萄糖的存在下,这种增加进一步增强。 Sulodexide表现出剂量依赖性的抑制30 mM D-葡萄糖诱导的PKC-βII和ERK磷酸化的作用,但对PKC-α或PKC-βI磷酸化没有影响。结论:我们的数据表明,虽然Sulodexide治疗可减少蛋白尿并改善肾脏它对DN的C57BL / 6小鼠肾脏的信号通路和基质蛋白合成具有不同的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号